NCT07244744Active, not recruiting
Tilrdakizumab Almirall
Investigating the Mechanisms of Short- and Long-term Responses to IL-23 Inhibition Using Tildrakizumab in Moderate to Severe Plaque Psoriasis Using High-definition Multiomics
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
Define the mechanisms underlying the short- and the long-lasting effects of IL-23 targeting in plaque PsO, by characterizing the longitudinal effects of IL-23 inhibition on the ratio of Trm/Treg cells in the skin of moderate to severe plaque PsO patients. HDST (Visium HD) and HDSP (MICS) are used to characterize the early (2 weeks) and late (16 weeks) molecular effects of treatment with tildrakizumab on the skin of three patients with moderate to severe plaque psoriasis. Non-lesional and lesional skin samples taken at the start of treatment with tildrakizumab will be used, as well as healed skin adjacent to the original sampling sites at week 2 and week 16 after the start of treatment with tildrakizumab. The same samples will be examined using Visium HD and the MACSima imaging system.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 3 (actual)
- First submitted
- 17 Nov 2025
- Start date
- 27 Jun 2023
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- University Hospital Schleswig-Holstein
- Diseases
- Psoriasis
- NCT number
- NCT07244744
What you commit to
- Study type: Observational
- Participants enrolled: 3
- From 27 Jun 2023 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to IL-23 inhibitors.
Other
- Patients unable to comply with the study requirements.
Who the study is looking for
- Adult patients (18 years or older) with a diagnosis of moderate to severe chronic plaque psoriasis.
- Patients eligible for treatment with an IL-23 inhibitor, specifically Tildrakizumab.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CCIM, Institut für Entzündungsmedizin UKSH Lübeck Coordinator of this site? Confirm its status | Lübeck | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.